ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 100,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $7.71, for a total value of $771,000.00. Following the transaction, the director now owns 210,346 shares of the company’s stock, valued at $1,621,767.66. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Laura Shawver also recently made the following trade(s):

• On Friday, August 4th, Laura Shawver sold 18,897 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $7.06, for a total value of $133,412.82.
• On Wednesday, August 2nd, Laura Shawver sold 36,281 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $7.09, for a total value of $257,232.29.
• On Monday, July 3rd, Laura Shawver sold 26,520 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $6.72, for a total value of $178,214.40.
• On Thursday, July 6th, Laura Shawver sold 33,510 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $6.34, for a total value of $212,453.40.

ARS Pharmaceuticals Stock Down 0.4 %

Shares of SPRY opened at $7.08 on Wednesday. ARS Pharmaceuticals, Inc. has a 1 year low of $3.99 and a 1 year high of $9.65. The business’s 50 day simple moving average is $6.90 and its 200-day simple moving average is $7.06.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The company had revenue of $0.01 million during the quarter. Research analysts predict that ARS Pharmaceuticals, Inc. will post -0.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an “outperform” rating and issued a $15.00 price target on shares of ARS Pharmaceuticals in a report on Monday, August 14th.

Institutional Trading of ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $64,000. Wells Fargo & Company MN bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $64,000. Teacher Retirement System of Texas bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $69,000. Arizona State Retirement System bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $71,000. Finally, American International Group Inc. bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $78,000. Hedge funds and other institutional investors own 57.41% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis.